Five Prime Therapeutics (Five Prime Therapeutics) Effective Interest Rate on Debt % : 0.00% (As of Dec. 2020)

View and export this data going back to 2013. Start your Free Trial

What is Five Prime Therapeutics Effective Interest Rate on Debt %?

Effective Interest Rate on Debt % is the usage rate that a borrower actually pays on a debt. It is calculated as the positive value of Interest Expense divided by its average total debt. Total debt equals to Long-Term Debt & Capital Lease Obligation plus Short-Term Debt & Capital Lease Obligation. Five Prime Therapeutics's annualized positive value of Interest Expense for the quarter that ended in Dec. 2020 was $0.00 Mil. Five Prime Therapeutics's average total debt for the quarter that ended in Dec. 2020 was $46.87 Mil. Therefore, Five Prime Therapeutics's annualized Effective Interest Rate on Debt % for the quarter that ended in Dec. 2020 was 0.00%.

Five Prime Therapeutics Effective Interest Rate on Debt % Historical Data

The historical data trend for Five Prime Therapeutics's Effective Interest Rate on Debt % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Five Prime Therapeutics Effective Interest Rate on Debt % Chart

Five Prime Therapeutics Annual Data

Trend

Dec11

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Effective Interest Rate on Debt %

Get a 7-Day Free Trial

Five Prime Therapeutics Quarterly Data
	Mar16	Jun16	Sep16	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20
Effective Interest Rate on Debt %	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of Five Prime Therapeutics's Effective Interest Rate on Debt %

For the Biotechnology subindustry, Five Prime Therapeutics's Effective Interest Rate on Debt %, along with its competitors' market caps and Effective Interest Rate on Debt % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Five Prime Therapeutics's Effective Interest Rate on Debt % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Five Prime Therapeutics's Effective Interest Rate on Debt % distribution charts can be found below:

* The bar in red indicates where Five Prime Therapeutics's Effective Interest Rate on Debt % falls into.

Five Prime Therapeutics Effective Interest Rate on Debt % Calculation

Five Prime Therapeutics's annualized Effective Interest Rate on Debt % for the fiscal year that ended in Dec. 2020 is calculated as

	Effective Interest Rate on Debt %
=	-1 * Interest Expense	/	( (Total Debt (A: Dec. 2019 )	+	Total Debt (A: Dec. 2020 ))	/ count )
=	-1 * 0	/	( (49.612	+	47.434)	/ 2 )
=	-1 * 0	/	48.523
=	0.00 %

where

	Total Debt (A: Dec. 2019 )
=	Long-Term Debt & Capital Lease Obligation	+	Short-Term Debt & Capital Lease Obligation
=	45.532	+	4.08
=	49.612

	Total Debt (A: Dec. 2020 )
=	Long-Term Debt & Capital Lease Obligation	+	Short-Term Debt & Capital Lease Obligation
=	42.309	+	5.125
=	47.434

Five Prime Therapeutics's annualized Effective Interest Rate on Debt % for the quarter that ended in Dec. 2020 is calculated as

	Effective Interest Rate on Debt %
=	-1 * Interest Expense	/	( (Total Debt (Q: Sep. 2020 )	+	Total Debt (Q: Dec. 2020 ))	/ count )
=	-1 * 0	/	( (46.301	+	47.434)	/ 2 )
=	-1 * 0	/	46.8675
=	0.00 %

where

	Total Debt (Q: Sep. 2020 )
=	Long-Term Debt & Capital Lease Obligation	+	Short-Term Debt & Capital Lease Obligation
=	42.103	+	4.198
=	46.301

	Total Debt (Q: Dec. 2020 )
=	Long-Term Debt & Capital Lease Obligation	+	Short-Term Debt & Capital Lease Obligation
=	42.309	+	5.125
=	47.434

In the calculation of annual Effective Interest Rate on Debt %, the Interest Expense of the last fiscal year and the average total debt over the fiscal year are used. In calculating the quarterly data, the Interest Expense data used here is four times the quarterly (Dec. 2020) interest expense data. Effective Interest Rate on Debt % is displayed in the 30-year financial page.

Five Prime Therapeutics (NAS:FPRX) Effective Interest Rate on Debt % Explanation

Effective Interest Rate on Debt % measures the usage rate that a borrower actually pays on a debt.

Five Prime Therapeutics Effective Interest Rate on Debt % Related Terms

Thank you for viewing the detailed overview of Five Prime Therapeutics's Effective Interest Rate on Debt % provided by GuruFocus.com. Please click on the following links to see related term pages.

Five Prime Therapeutics (Five Prime Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Five Prime Therapeutics Inc (NAS:FPRX) » Definitions » Effective Interest Rate on Debt %

Comparable Companies

Traded in Other Exchanges

N/A

Address

111 Oyster Point Boulevard, South San Francisco, CA, USA, 94080

Website

http://www.fiveprime.com

Five Prime Therapeutics Inc is a biotechnology company focused on discovering and developing protein therapeutics for diseases. The company's product candidates address patient populations for which therapies are still needed. It is focused on advancing its internal pipeline and retaining rights for products in targeted specialty markets. It also seeks to establish additional collaborations to supplement its internal development capabilities. These collaborations generate additional funding in order to further validate the company's technology. It has the following product in the pipeline: Cabiralizumab, FPA150, FPT155, and Bemarituzumab.

Executives

William R Ringo	director
Biotechnology Value Fund L P	10 percent owner	44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO CA 94104
Bvf Gp Holdings Llc	10 percent owner	44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104
Bvf Ii Gp Llc	other: See Explanation of Responses	44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104
Bvf I Gp Llc	10 percent owner	44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104
Bvf Partners Os Ltd.	other: See Explanation of Responses	P.O. BOX 309 UGLAND HOUSE, GRAND CAYMAN E9 KY1-1104
Biotechnology Value Trading Fund Os Lp	other: See Explanation of Responses	P.O. BOX 309 UGLAND HOUSE, GRAND CAYMAN E9 KY1-1104
Mark N Lampert	10 percent owner	1 SANSOME ST, 30TH FL, SAN FRANCISCO CA 94104
Biotechnology Value Fund Ii Lp	other: See Explanation of Responses	44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO CA 94104
Bvf Partners L P/il	10 percent owner	44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104
Bvf Inc/il	10 percent owner	44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO CA 94104
David White	officer: See Remarks	4560 HORTON STREET EMERYVILLE CA 94608
Helen Louise Collins	officer: EVP and Chief Medical Officer	TWO CORPORATE DRIVE, SOUTH SAN FRANCISCO CA 94080
Franklin M Berger	director	1000 MARINA BLVD, STE 200, BRISBANE CA 94005
Garry A Nicholson	director	C/O TESARO, INC., 1000 WINTER STREET, SUITE 3300, WALTHAM MA 02451